Growth masked by margin squeeze
Revenue jumped 18% year-on-year, but profits fell 16.6% — a divergence that explains why management cut FY27 guidance by ₹50 crore. The quarter exposes structural cost pressures the company is still working through.
₹130.5 Cr
+18.1% YoY
₹8.8 Cr
-16.6% YoY
6.7%
vs ~8% prior year
14.7%
vs 18% target
On the surface Q2 looks like a solid quarter: revenue hit ₹130.5 crore, a healthy 18% year-on-year climb. But the profit story tells a different tale. Net profit fell 16.6% to ₹8.8 crore despite that top-line growth. That gap — the divergence between what revenue is doing and what profit is doing — is the quarter's defining story.
Where the margin went
Sigachi's Q2 EBITDA came in at ₹19.2 crore, a 14.72% margin. Management had guided for an 18% full-year average. That's a 328 basis point miss in a single quarter. The company is betting on H2 to deliver margins of 18% or higher to make up the shortfall — but the structural headwind is visible: rising input costs or pricing pressure (or both) are squeezing the bottom line even as sales grow. The net profit margin compressed from roughly 8% last year to 6.7% this quarter. Price realization has improved — the company achieved ₹262.83 per unit in Q2 vs ₹241.36 in Q1 — a 21.6% year-on-year jump. But that price strength is not enough to offset cost inflation.
Q2+ will see quarter-on-quarter revenue and margin improvement
Revenue +7.6% QoQ (Q2 vs Q1), PAT +7.8% QoQ. But YoY PAT fell 16.6% — margin squeeze persists.
Overstated
FY27 revenue target of ₹650–675 Cr is achievable
CFO revised guidance to ~₹600 Cr due to MCC expansion delay from Q1 FY28 to Q2 FY28.
Contradicted
Full-year EBITDA margin will average 18%
Q2 delivered 14.72%. H2 would need 18%+ to achieve the annual target. Execution risk high.
At Risk
MCC 12K MTPA expansion and CCS 1.8K MT facility to commission Q2 FY28
Still on track for Q2 FY28, but delayed 6 months from the Q1 FY28 initial timeline.
Delayed, not off
What changed on this call
Revenue guidance slashed ₹50 crore: The big headline. From ₹650 crore down to ~₹600 crore. That's a 7.7% haircut driven entirely by the 6-month postponement of the MCC capacity expansion from Q1 FY28 to Q2 FY28. H1 FY27 has delivered ₹250 crore, so H2 needs ₹350 crore to hit the ₹600 crore full-year target. That's more plausible than the prior ₹650–675 guidance, but still hinges on execution.
API order book ramp — the upside flag: The company's active pharmaceutical ingredients business achieved a ₹38 crore order book in Q2 and is targeting ₹100+ crore by year-end. Q2 API revenue was ₹16.7 crore (13% of total), but management indicated that some Q2 revenue was deferred to Q3 at customer request. The trajectory is the story here: API is moving from a niche contributor to a material driver of both growth and margins (higher-margin co-processed grades are the focus).
Capacity utilization constrained — but temporary: The Hyderabad plant accident earlier in the year forced a safety audit. MCC is running at ~80% utilization, well below capacity. Management flagged that post-November (after safety clearance), the plant can ramp to full capacity. It's a near-term headwind masking the pricing power story.
How the street is positioned
The stock sits at ₹28.1, well above its 52-week low of ₹16.65 and well below its all-time high of ₹95.9 (down 70.7% from the peak). Against the 50-day average (SMA50) at ₹29.94, the stock trades just below; against the 200-day average (SMA200) at ₹24.33, it trades above. Technicals are neutral (RSI 53). But the ownership story is more telling: Foreign institutional investors have trimmed from 3.33% two quarters ago to just 1.25% now — a consistent drift lower. Domestic institutional investors remain absent (0.00%). Promoters hold steady at 36.69%, suggesting no insider selling alarm. An ETF rebalance (SPDR) dumped 37.3 lakh shares on 18 September at ₹29.83, mechanical rather than informed, but the volume trend is now increasing post-result — a sign of renewed retail/short-cover interest, though not institutional conviction.
The market's read is clear: skepticism. The stock's 70% drawdown from ATH reflects the broader sell-off in specialty pharma and the guidance misses. The recent FII trim suggests the street is rotating out, waiting for proof of the margin recovery story and the API ramp. Post-result, volume is picking up, but price hasn't rebounded sharply — there's interest, but not conviction.
Revenue growth solid at +18.1% YoY; volume and price both contributing
Price realization up 21.6% YoY; pricing power evident vs. commodity peers
API order book ₹38 Cr; on track for ₹100+ Cr by year-end
Long-term capacity (30K MTPA post-FY28) structures multi-year optionality
PAT fell 16.6% YoY despite +18% revenue — margin squeeze unresolved
EBITDA margin 14.7% vs 18% target; H2 recovery assumption is aggressive
FY27 guidance cut ₹50 Cr (7.7%); credibility dented
MCC capex delayed 6 months; further delays risk FY28 trajectory
Capex funding (₹200 Cr) still TBD; debt/equity split unclear; refinancing risk
FII trimming (3.33% → 1.25%); institutional confidence waning
Margin compression is structural, not temporary
HighQ2 PAT fell 16.6% despite revenue +18%. Input cost inflation or pricing weakness (or both) is real. If H2 doesn't recover to 18%+ margin, FY27 guidance will miss again and confidence will collapse.
MCC capex delays further
HighAlready 6 months late (Q1 FY28 → Q2 FY28). Another slip pushes the 30K MTPA capacity target and FY28 earnings tailwind further out. Market is priced for execution; slippage triggers re-rating.
API order book doesn't materialize
High₹38 Cr order book is visible, but realization risk is real. If Q3-Q4 API revenue disappoints, the growth story for FY28+ loses credibility and the stock re-rates lower.
Capex funding & debt burden
Medium₹200 Cr capex needs funding; debt/equity split TBD. If debt is raised at higher rates or equity dilutes significantly, per-share accretion is at risk. Refinancing in a rising-rate environment is a headwind.
Hyderabad accident follow-up reputational or operational hit
MediumSafety constraints are currently limiting utilization to 80%. If there's a follow-up incident or audit failure, demand could weaken and margins compress further.
Stock valuation doesn't leave room for disappointment
MediumDespite the 70% drawdown from ATH, the stock is not cheap at forward multiples. If the company misses H2 margin guidance or API ramp-up slows, there's limited upside and meaningful downside. The market has already priced out the bull case; execution is not optionality.
1 · Q3 API revenue — the margin recovery catalyst
Q2 saw some API customers defer to Q3. That deferred revenue could push Q3 API above ₹16.7 Cr and demonstrate the ramp trajectory. If it does, margins should expand (higher-margin co-processed grades). That's the rebuttal to the bear case. Watch the call narrative closely.
2 · H2 EBITDA margin trends — can the company defend 18%?
Full-year 18% EBITDA margin requires H2 to be 18%+ to offset Q2's 14.7%. That means either: (a) input costs stabilize/decline, or (b) volume/mix improve enough to offset cost pressure, or (c) pricing power holds. Any of these is possible; all are execution. If H2 Q3 comes in below 17%, the 18% target will miss and credibility will be forfeited.
3 · MCC expansion construction milestone — track civil & equipment status
Management says 'one year timeline' to Q2 FY28. Watch for investor updates and Q3 call commentary on civil structure completion, equipment procurement, and commissioning readiness. A second 6-month slip would be a major de-rating event.
4 · Capex funding announcement — debt vs. equity split
The company still hasn't announced how it will fund the ₹200 Cr capex. Insurance receivable (~₹49 Cr net) is expected by Nov-Dec, which eases immediate pressure. But the debt/equity mix matters. High debt adds refinancing risk; high equity dilutes the per-share story.
Sigachi Q2 is a transition quarter masquerading as a growth quarter. Revenue is accelerating and price realization is improving — both are real and material. But the profit collapse tells the honest story: the company is caught between a low-margin, commodity-driven past and a higher-margin, specialty-driven future. That transition is where the value is, but the near-term execution is messier than the guidance (or the market) wants to believe.
The guidance cut from ₹650 Cr to ₹600 Cr is the call's most important moment. It flags that the company is recalibrating expectations — and that the MCC expansion delay is not a cosmetic slip but a material cash-flow and earnings headwind. The margin miss (14.7% vs 18%) is the second. Together, they say: execution is harder than management signaled, near-term is at risk, but long-term optionality (30K MTPA MCC, API scaling) is still there.
For a holder, the key number to watch is not revenue or even profit — it's the H2 EBITDA margin. If it lands at 18% or above, management credibility recovers and the stock re-rates. If it misses again, Sigachi will need to deliver API scale-up or MCC ramp-up proof to restore confidence. At ₹28.1, the stock is pricing in structural risk and a prolonged transition. The upside is there, but it's contingent on execution. The debate is not closed; the next quarter will decide.
Sigachi Q2: PAT -17% YoY on one-off comp; adjusted profit +50%, margins expand
PAT -16.6% YoY · revenue +18.1% · margins expanding
₹130.46 Cr
+18.1% YoY
₹8.78 Cr
-16.6% YoY
6.72%
-2.6pp YoY
₹0.27
Sigachi's consolidated revenue rose 18.1% YoY and 7.6% QoQ to ₹130.46 Cr, but reported consolidated PAT of ₹8.78 Cr looks like a 16.6% YoY decline against last year's ₹10.53 Cr. That comparison is distorted: the year-ago quarter (Q2 FY26) booked a ₹4.66 Cr exceptional gain tied to the June 2025 Hyderabad Pashamylaram fire (a partial reversal of the ~₹121 Cr exceptional loss booked in Q1 FY26), while this quarter has no exceptional item at all. Strip that one-off from the base and adjusted YoY PAT growth is +49.5% (standalone adjusted growth is a smaller +26.4%, with the gap explained by the subsidiary swinging from a larger net-loss drag last year to a much smaller one now) — the real story is a solid profit recovery, not a decline.
Q2 FY-2027 vs prior quarters
Margins back this up: operating margin (EBITDA/revenue) expanded to ~14.65% this quarter from 13.62% in Q1 FY27 and roughly 6.8% in Q2 FY26 (confirmed against external reporting of that quarter's 6.78% EBITDA margin, since the fire aftermath was still depressing margins then). Net margin was roughly flat sequentially at 6.73% versus 6.66% in Q1, but down from 9.32% a year ago purely because of the exceptional-gain-inflated base. The quarter therefore delivered the sequential revenue-and-margin improvement management flagged for "Q2 and beyond" on the August 2026 call.
The stock went into the print at ₹26.4, down 8.2% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Standalone PAT ₹8.98 Cr, basic EPS ₹0.23, close to consolidated PAT ₹8.78 Cr and EPS ₹0.27 (consol EPS computed on ₹10.18 Cr shareholders' share)
FY27 revenue ₹650-675 Cr (maintained); full-year EBITDA margin 18% (maintained). Q2+ should see quarter-on-quarter revenue/margin improvement. 12,000 MTPA MCC expansion and 1,800-ton CCS facility to commission Q2 FY28 (delayed from Q1 FY28). API business targeting >₹100 Cr annual run-rate.
— This quarter: met
Against the full FY27 guidance of ₹650-675 Cr revenue and 18% EBITDA margin (both maintained since that call), H1 FY27 revenue of ₹251.73 Cr means H2 must run at roughly double H1's pace to clear even the low end — a material stretch not yet evidenced in this print. H1 OPM of ~14.2% also trails the 18% full-year target, so margin needs to keep climbing through Q3-Q4. No analyst consensus or brokerage preview for this specific quarter could be found via web search, so vsStreet is marked unknown rather than guessed; no standalone management press release was available either to cross-check the company's own framing of the quarter, so this summary relies on the filing itself. Separately, the company's 12,000 MTPA MCC expansion and 1,800-ton CCS facility remain pushed to Q2 FY28 (previously Q1 FY28), and a September 9 EGM corrigendum on a preferential issue points to capital-raising likely tied to funding that delayed capacity build-out.
W1
H2 FY27 revenue must run at roughly double H1's ₹251.73 Cr pace to hit management's ₹650-675 Cr FY27 guidance
W2
Full-year EBITDA margin guided at 18% vs H1 FY27 running at ~14.2% — margin trajectory into Q3/Q4 needs to be verified
W3
12,000 MTPA MCC expansion and 1,800-ton CCS facility commissioning, now guided for Q2 FY28 — confirm no further slippage
Figures in ₹ Lakhs in source, converted to Cr. Consol PAT ₹8.78 Cr is total 'profit for the period' (pre-NCI split, matches our DB's historical basis); shareholders' share is ₹10.18 Cr and EPS 0.27 is computed on that. Year-ago quarter (Q2 FY26) carried a ₹4.66 Cr exceptional gain (fire-insurance related, partly reversing Q1 FY26's ~₹121 Cr fire loss) vs nil exceptional this quarter — adjusted below for comparability. Standalone (₹8.98 Cr) and consol (₹8.78 Cr) PAT are close in absolute terms but adjusted YoY growth diverges (~26% standalone vs ~50% consol) due to the subsidiary's narrower net loss this year vs last.
Revenue growth masks PAT collapse; guidance cut
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Guidance cut material (₹650 Cr → ₹600 Cr). EBITDA margin Q2 at 14.7%, well below 18% target. Execution delayed.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered revenue growth (+18.1% YoY) but PAT collapsed (-16.6% YoY), signaling margin compression despite higher sales. Management cut FY27 revenue guidance to ~₹600 Cr from ₹650 Cr due to MCC expansion deferment. Long-term optionality from capacity investments is material but contingent on execution; near-term margin recovery is at risk.
₹130.5 Cr
Revenue · +18.1% YoY₹8.8 Cr
Reported PAT · −16.6% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Total operating income INR 130.45 crores
METDelivered result shows ₹130.5 Cr
Net profit INR 8.78 crores, 6.82% margin
METDelivered ₹8.8 Cr at 6.7% NPM
EBITDA INR 19.2 crores, 14.72% margin for Q2
METImplied from revenue ₹130.5 Cr; margin compression evident YoY
Q2+ will see quarter-on-quarter revenue/margin improvement
OVERSTATEDQoQ revenue +7.6%, PAT +7.8% vs Q1; but YoY PAT -16.6% shows margin squeeze
FY27 revenue ₹650 Cr achievable
MISSCFO explicitly states ~₹600 Cr now due to MCC delay
Earnings quality
What changed since the last call
FY27 revenue guidance
DowngradeCut from ₹650 Cr to ~₹600 Cr due to MCC 12K MTPA expansion delay from Q1 FY28 to Q2 FY28
EBITDA margin trajectory
DowngradeQ2 at 14.72%, below 18% target. Management now pins recovery on H2 achieving 18%+ to average the year.
MCC expansion capex
NeutralTotal capex ~₹30 Cr (civil ₹25 Cr + plant/machinery phased). 6-month deferment means cash flow timing shift, not amount change.
API business momentum
UpgradeOrder book ₹38 Cr achieved; targeting ₹100 Cr by year-end. Q1 run-rate ₹35-40 Cr, growing.
The Q&A
Analysts pressed hard on revenue guidance (Darshil Jhaveri, Crown Capital), margin recovery realism (Darshil on 18% EBITDA), and capacity delays (Vansh Solanki, RSPN on utilization vs. cost structure). Management acknowledged delays, safety constraints limiting utilization, but held defensively on H2 recovery. Some evasion on capex funding and debt ceiling.
FY27 guidance reset — Darshil Jhaveri, Crown Capital
AnsweredOriginal target ₹650 Cr feasible if MCC came on-time, but delayed to Q2 FY28. Now targeting ~₹600 Cr (up from ₹250 Cr H1).
EBITDA margin recovery — Darshil Jhaveri, Crown Capital
PartialYes, expecting at least 18% in H2 to balance out. Q2 at 14.72% was held back by fixed overhead absorption; margin mix to improve with special grades and co-processed variants in Q3-Q4.
Capacity delays — Vansh Solanki, RSPN Ventures
AnsweredPost-Hyderabad accident, prioritized safety audits and installation of precautionary equipment. Lower utilization is deliberate. Post-November, safety done; capacity ramp can resume.
API business growth — Rupesh Tatiya, Long Equity Partners
AnsweredAt ₹38 Cr achieved; targeting ₹100 Cr by year-end. With value-added products (sparsentan, benzenesulfonic acid), can stretch to ₹120-150 Cr. Multiple customers, good demand.
Capex funding & debt — Ankur Savaiya, unidentified
DodgedBoth debt and equity options open. Banks supportive. Will announce after board discussions. Insurance receivable (~₹49 Cr, ~₹44 Cr net after 10% discount) also expected by Nov-Dec.
Guidance
FY27 ~₹600 Cr (cut from ₹650 Cr)
MediumH1 ~₹250 Cr achieved. H2 needs ~₹350 Cr. MCC expansion deferred to Q2 FY28 is the constraint.
Beyond FY27: ₹800 Cr possible
LowFY28+ assumes MCC 12K MTPA + CCS 1.8K MT both operational; speculative.
EBITDA margin 18% full-year FY27
MediumQ2 at 14.72%. Management expects H2 ≥18% to average out. Contingent on cost absorption and mix improvement.
H2 FY27 margin at least 18%
LowSales mix toward special grades and co-processed variants. But execution risk from capacity ramp timing and price realization.
MCC 12K MTPA + CCS 1.8K MT capex ~₹200 Cr total
MediumAlready ₹25 Cr civil + ₹30 Cr for plant/machinery incurred. Remaining ~₹145 Cr. Funding via debt + equity (TBD).
Risks the call surfaced
Execution risk — capex delays
HighMCC 12K MTPA now deferred to Q2 FY28 from Q1 FY28 (6-month slip). Further delays could push FY28 contribution out, impacting FY28-FY29 revenue trajectory.
Margin compression — structural
HighQ2 EBITDA margin 14.72%, well below 18% target. PAT fell 16.6% YoY despite +18% revenue. Suggests rising COGS or lower pricing power.
Capacity utilization — safety constraints
MediumPost-Hyderabad accident, plant running at ~80% utilization due to safety audits and precautionary equipment installation. Limits upside from existing assets.
Guidance credibility — cut precedent
MediumFY27 revenue guidance lowered from ₹650 Cr to ~₹600 Cr (8% cut). EBITDA margin target 18% at risk (Q2 only 14.72%). Reduces credibility on forward statements.
API growth — customer concentration risk
MediumAPI segment revenue ₹16.7 Cr in Q2. Target ₹100 Cr+ by year-end is ambitious. Q2 saw some customer deferrals to Q3. Order book ₹38 Cr is visible but realization uncertain.
Management
Score 6/10. Direct on numbers but vague on capex funding and debt strategy. Transparent on delays and safety focus. Hedged on margin recovery timeline (18% 'expected' not committed). Mixed. Hit H1 ₹250 Cr but guided down FY27 from ₹650 Cr to ₹600 Cr. MCC capex 6-month slip. EBITDA target at risk.
1 · Q2-Q4 FY28
12,000 MTPA MCC + 1,800-ton CCS facility commissioning; could lift total MCC capacity to 30,000 MTPA
2 · Q3 FY27
Deferred API revenue (₹30+ Cr) expected to arrive; capacity utilization ramp post-safety clearance
3 · Q4 FY27
MCC capacity targeting 4,500 metric tons/quarter; H2 margin improvement to 18%+ to meet annual guidance
Long-term optionality from capacity investments is material but contingent on execution; near-term margin recovery is at risk.